Pharmacyte Biotech, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
PharmaCyte Biotech's Form 10-K filing reveals ongoing challenges with an FDA clinical hold on its pancreatic cancer therapy, impacting development timelines and requiring significant resources to address regulatory concerns.
NASDAQ
PharmaCyte Biotech reports a significant net income increase driven by investment gains, while facing ongoing FDA clinical hold challenges and strategic reevaluation of its core cancer therapy programs.
NASDAQ
PharmaCyte Biotech's annual report reveals a year of strategic reevaluation, reduced spending, and ongoing efforts to address an FDA clinical hold on its pancreatic cancer therapy.